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Objective: To evaluate the impact of lung function, measured as forced expiratory volume in
1 second (FEV1) % predicted, on health care resource utilization and costs among patients with
COPD in a real-world US managed-care population.
Methods: This observational retrospective cohort study utilized administrative claim data augmented with medical record data. The study population consisted of patients with one or more
medical claims for pre- and postbronchodilator spirometry during the intake period (July 1, 2012
to June 30, 2013). The index date was the date of the earliest medical claim for pre- and postbronchodilator spirometry. Spirometry results were abstracted from patients’ medical records. Patients
were divided into two groups (low FEV1% predicted [,50%] and high FEV1% predicted [$50%])
based on the 2014 Global Initiative for Chronic Obstructive Lung Disease report. Health care
resource utilization and costs were based on the prevalence and number of discrete encounters
during the 12-month postindex follow-up period. Costs were adjusted to 2014 US dollars.
Results: A total of 754 patients were included (n=297 low FEV1% predicted group, n=457 high
FEV1% predicted group). COPD exacerbations were more prevalent in the low FEV1% predicted
group compared with the high group during the 12-month pre- (52.5% vs 39.6%) and postindex
periods (49.8% vs 36.8%). Mean (standard deviation) follow-up all-cause and COPD-related costs
were $27,380 ($38,199) and $15,873 ($29,609) for patients in the low FEV1% predicted group,
and $22,075 ($28,108) and $10,174 ($18,521) for patients in the high group. In the multivariable
analyses, patients in the low FEV1% predicted group were more likely to have COPD exacerbations
and tended to have higher COPD-related costs when compared with patients in the high group.
Conclusion: Real-world data demonstrate that patients with COPD who have low FEV1%
predicted levels use more COPD medications, have more COPD exacerbations, and incur higher
COPD-related health care costs than those with high FEV1% predicted levels.
Keywords: COPD, lung function, FEV1, exacerbations, health care resource utilization and
costs
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COPD is characterized by a restricted airway and functional impairment. 1 The
symptoms of COPD, including dyspnea, cough, and sputum production, negatively
affect a patient’s health status and may lead to disability. Airflow restriction is
progressive and often not spontaneously reversible; therefore, the goal of COPD
therapy is to reduce symptoms, prevent exacerbations, and improve lung function.
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) classifies COPD
based on history of exacerbations and symptoms, as well as objective measures of
airflow limitation.2 Spirometry – specifically, forced expiratory volume in 1 second
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(FEV1) – is a widely accepted objective and validated
measure of pulmonary function.3–5 The US Food and Drug
Administration requires spirometry improvements as a primary outcome in clinical trials of bronchodilator medications
for COPD. In clinical practice, however, patient symptoms
and health status are commonly used for clinical assessment
of COPD.6
Numerous studies have demonstrated a correlation
between poor lung function and increased COPD symptoms
and exacerbations,7–17 and improvements in lung function are
associated with health status gains in people with COPD.6
Studies examining the relationship between FEV1 and
patient-reported outcomes concluded that changes in FEV1
predict changes in health status.6,11 Therefore, therapies
that improve FEV1 will likely improve clinical and patientreported outcomes as well.11
COPD exacerbations are often sufficiently serious to
require emergency treatment or hospitalization,16 and are
thus associated with substantial increases in health care
costs.17 A retrospective study measuring the cost of COPD
exacerbations, identified from administrative claim data
and assessed by quarter and severity of the exacerbation,
found the mean total cost of a severe exacerbation (ie, an
exacerbation [with a claim for oral or parenteral cortico
steroids on the same day or within 7 days following a
COPD claim] involving either a hospitalization on the
same day or death within 7 days of the COPD claim) was
US $17,016 per patient-quarter, compared with $6,628 per
patient-quarter for a nonsevere exacerbation (ie, an exacerbation involving neither a hospitalization on the same
day nor death within 7 days of the COPD claim).17 While
previous research has largely examined the relationship
between claim-determined exacerbations and costs, studies
that have explored the relationship between clinically
determined lung function (ie, measured by spirometry) and
health care resource utilization (HCRU) and costs18–30 are
limited to studies based on data gathered more than a decade
ago,21,22,26,29 populations of fewer than 500 patients,22,25,27,28
or patients recruited from single centers.26,27,30 Additionally, a number of those studies were performed outside
the US.18–21,23–25,28,29 Since COPD treatment and health care
utilization patterns, as well as costs, vary considerably
between countries,28 the results from these studies, while of
interest, cannot be generalized to a US population. To fill
this knowledge gap, this study evaluated the impact of
FEV1 levels on HCRU, including COPD exacerbations, and
direct costs among patients with COPD in a real-world US
managed-care population.
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Methods
Study design and patient identification
This study was an observational retrospective cohort study
utilizing administrative claim data augmented with medical
record data. The patient sample was identified from medical
and pharmacy claims in the HealthCore Integrated Research
Database, a large administrative claims database with
claims from 14 geographically dispersed US health plans,
with service dates during the study period between July
1, 2011 and June 30, 2014. The patient inclusion criteria
based on administrative claims data were: one or more
medical claims for pre- and postbronchodilator spirometry
(Current Procedural Terminology code 94060) during the
study intake period, which extended from July 1, 2012
through June 30, 2013 (index date = date of the earliest
medical claim for pre- and postbronchodilator spirometry
in the intake period); one or more medical claims for an
inpatient stay or emergency department (ED) visit associated with COPD (International Classification of Diseases,
ninth revision, clinical modification [ICD-9-CM] diagnosis
codes 491.xx, 492.xx, and 496.xx); or two or more medical
claims with distinct service dates for COPD in an office or
other outpatient setting during the study period. In addition,
all patients were 40 years of age or older on the index date,
had at least 12 months preindex (baseline) and 12 months
postindex (follow-up) continuous medical and pharmacy
enrollment, were insured with only commercial or Medicare
Advantage health insurance during the study period, and
were patients whose medical records could be requested for
medical record studies (Figure 1).

Medical record review
Medical record data were required to supplement information
not available in the administrative claims data (eg, FEV1%
predicted value). Providers who were associated with the
index spirometry test who had seen the patient at least once
in the 12-month period prior to the index date and had valid
contact information, were identified. A patient/provider
list was generated and sent to HealthCore’s medical record
vendor, who requested the medical records of the patients
on the list from their identified providers. A standardized
data collection form was developed and used to abstract the
relevant clinical data. Patients with a diagnosis of COPD,
a postbronchodilator FEV1/forced vital capacity (FVC)
ratio ,0.7, and at least one post-bronchodilator FEV1%
predicted value documented in the medical record review
period, defined as between index date - 365 days and index
date + 30 days, were included in the analyses.
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Figure 1 Study design.

The number of targeted completed medical record
abstractions was set at 800, based on margin-of-error
estimations ranging from ±4.9% to ±6.57% at a 95% confidence level. The study was approved by the New England
Institutional Review Board. A Waiver of Authorization
was obtained from the New England Institutional Review
Board to acquire and review medical records without patient
signature.
After the medical record abstractions were completed,
patients’ medical record data were merged with their administrative claims data using unique patient identifiers for
analysis purposes. The patient cohort was stratified into two
groups, based on the postbronchodilator FEV1% predicted
value according to the classification of severity of airflow
limitation in COPD specified in the 2014 GOLD report.2
Patients meeting the GOLD criteria for mild (GOLD I) or
moderate (GOLD II) COPD severity (ie, postbronchodilator
FEV1 50% predicted or higher) were categorized as high
FEV1% predicted, and patients meeting the GOLD criteria
for severe (GOLD III) or very severe (GOLD IV) COPD
(ie, FEV1 less than 50% predicted) were categorized as low
FEV1% predicted.

Study measures
Baseline variables assessed from the administrative claims
included demographic characteristics (eg, age, sex, provider
specialty associated with index spirometry test) and clinical
characteristics during the 12-month preindex period, such as
comorbidities (measured using the Quan–Charlson Comorbidity Index)31 and conditions, use of oxygen therapy, and
dyspnea. Criteria for COPD exacerbations were based on the

International Journal of COPD 2016:11

2014 GOLD report,2 and were defined as inpatient COPD
exacerbations (an inpatient stay with COPD [ICD-9-CM
codes 491.xx, 492.xx, 496.xx] as the primary diagnosis),
ED COPD exacerbations (an ED visit with COPD as the
primary diagnosis [ED visits followed by hospitalizations were not included, as they were considered inpatient
hospitalizations]), and ambulatory COPD exacerbations
(a physician office or other outpatient visit with COPD
diagnosis in any position of a medical claim and receipt of
corticosteroids and antibiotics within 7 days following the
physician office/other outpatient visit) during the 12-month
pre- and 12-month postindex periods. The hierarchy applied
to create the type of COPD exacerbation for an exacerbation
episode was inpatient COPD exacerbation . ED COPD
exacerbation . ambulatory COPD exacerbation. COPD
medication treatment patterns were evaluated at 12 months
pre- and 12 months postindex, and included any inhaled corticosteroids (ICS), long-acting muscarinic agents (LAMAs),
long-acting β-agonists (LABAs), short-acting muscarinic
antagonists, or short-acting inhaled β2-adrenergic agonists
used as a single or combination therapy in addition to other
COPD medications, including phosphodiesterase-4 inhibitors and xanthenes.
HCRU and costs were based on the prevalence and
number of discrete encounters during the 12-month pre- and
12-month postindex periods. Utilization was broken down
by site of care (eg, physician office visits, other outpatient
visits, ED visits, and inpatient hospitalizations) and pharmacy
dispensing. Costs were determined based on site of care,
and were reported in aggregate as total costs paid across all
resources (medical plus pharmacy) in US dollars. Costs are
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presented as the combined amount paid by both the health
plan and the patient to providers. Patient out-of-pocket costs
included all coinsurance, deductibles, copayments, or other
patient outlays related to specific medical claims. All costs
were adjusted to 2014 dollars, given the most recent medical care price index information provided by the Bureau of
Labor Statistics at the time the analyses were performed.32
COPD-related utilization and costs were captured from medical claims containing ICD-9-CM diagnosis codes for COPD
(ICD-9-CM codes 491.xx, 492.xx, and 496.xx) and pharmacy
claims containing generic product identifier codes for COPDrelated medications. Additional clinical data abstracted from
the medical records included confirmation of the COPD
diagnosis, spirometry test results, asthma diagnosis, dyspnea,
smoking status, and race.

Statistical analyses
Descriptive statistics included means (standard deviation
[SD], median) and frequencies and percentages for continuous and categorical data, respectively. An unadjusted
analysis was conducted with comparisons between high
and low FEV1% predicted cohorts. Logistic regression
models were developed to examine the association between
postbronchodilator FEV1% predicted and occurrence of
COPD exacerbations in the 12-month postindex period. The
dependent variable was occurrence of at least one COPD
exacerbation in the 12-month follow-up period. Due to the
non-normal distribution and skewed nature of the cost data,
generalized linear models with gamma distribution and
log link function were applied to examine the association
between postbronchodilator FEV1% predicted and all-cause
health care direct costs in the 12-month postindex period, and
the association between postbronchodilator FEV1% predicted
and COPD-related health care direct costs in the 12-month
postindex period. Analyses were performed using SAS 9.4
(SAS Institute Inc, Cary, NC, USA), with a two-sided 5%
significance level for all statistical tests.

Results
Study population
Of the 4,349 patients who were identified from the administrative claims database (Figure S1) and whose medical
records were requested, 2,507 medical records were obtained
and 2,480 medical records reviewed for eligibility criteria.
Of these, the medical records of 754 patients contained all
required clinical data, and were included in the final analysis
(Figure S2); 1,726 medical records were excluded, because
there were no documented spirometry results (644 records),
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no documented postbronchodilator FEV1% (246 records), no
documented postbronchodilator FEV1/FVC ratio ,0.7 (731
records), no documented diagnosis of COPD (85 records),
or incorrect patient information (20 records).

Baseline patient characteristics from
claims data
The mean age of patients included in the analyses was 69.4
(SD 8.81) years in the low FEV1% predicted group and
71.3 (SD 9.97) years in the high FEV1% predicted group
(Table 1). Slightly more than half were women (54.4%).
Pulmonologists were the predominant provider specialty
associated with the index spirometry tests in both the low
FEV1% predicted group (79.8%) and high FEV1% predicted
group (73.3%).
The most prevalent comorbidities in both cohorts were
hypertension (57.6% low group vs 63.5% high group),
ischemic heart disease (27.3% low group vs 28.4% high
group), and diabetes (23.6% low group vs 22.5% high group).
Compared with patients in the high FEV1% predicted group,
a greater percentage of patients in the low FEV1% predicted
group had oxygen therapy (42.1% low group vs 19.0% high
group) during the baseline period.

Baseline clinical characteristics from
medical records
All 754 patients had a diagnosis of COPD confirmed in their
medical records. The mean (SD) postbronchodilator FEV1%
predicted values were 37.2% (8.38%) and 69.1% (14.51%) in
the low and high FEV1% predicted groups, respectively. The
mean (SD) postbronchodilator FEV1/FVC ratio was 45.5%
(10.71%) in the low FEV1% predicted group and 58.8%
(7.58%) in the high FEV1% predicted group. A majority of
patients were Caucasian/white (82.8% low group vs 79.4%
high group), had experienced dyspnea (77.4% low group vs
70.5% high group), and had a history of smoking (74.1%
low group vs 76.8% high group). An asthma diagnosis was
documented in 17.2% of patients in the low FEV1% predicted
group vs 19.9% in the high group (Table 2).

Utilization of COPD medications from
claims data
Among patients in the low and high FEV1% predicted groups,
utilization of COPD medications during the baseline and
follow-up periods were: any ICS (67.3% vs 46% and 70.7%
vs 54.9%), any LABA (66.3% vs 41.8% and 68.4% vs
51%), any LAMA (51.2% vs 35.7% and 54.5% vs 41.6%),
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Table 1 Baseline demographic and clinical characteristics from claims

Female, n (%)
Age at index (years), mean (SD, median)
Age group, n (%)
40–64 years
65–74 years
$75 years
Provider specialty associated with index
spirometry test, n (%)
Pulmonologist
Primary care physicianb
Other
Most prevalent comorbidities, n (%)
Hypertension
Ischemic heart disease
Diabetes
Asthma
Peripheral vascular disease
COPD-related infection
Congestive heart failure
Cancer
Heart failure
Atrial fibrillation
Cerebrovascular disease
Oxygen therapy, n (%)
Dyspnea, n (%)
QCI, mean (SD, median)

Total
(n=754)

Low FEV1%
predicteda (n=297)

High FEV1%
predicteda (n=457)

410 (54.4)
70.6 (9.57, 72)

154 (51.9)
69.4 (8.81, 70)

256 (56.0)
71.3 (9.97, 72)

199 (26.4)
279 (37.0)
276 (36.6)

82 (27.6)
126 (42.4)
89 (30.0)

117 (25.6)
153 (33.5)
187 (40.9)

572 (75.9)
161 (21.4)
21 (2.8)

237 (79.8)
52 (17.5)
8 (2.7)

335 (73.3)
109 (23.9)
13 (2.8)

461 (61.1)
211 (28.0)
173 (22.9)
165 (21.9)
140 (18.6)
138 (18.3)
124 (16.4)
109 (14.5)
105 (13.9)
98 (13.0)
80 (10.6)
212 (28.1)
369 (48.9)
2.5 (1.99, 2)

171 (57.6)
81 (27.3)
70 (23.6)
63 (21.2)
55 (18.5)
58 (19.5)
50 (16.8)
34 (11.4)
43 (14.5)
28 (9.4)
31 (10.4)
125 (42.1)
159 (53.5)
2.4 (1.97, 2)

290 (63.5)
130 (28.4)
103 (22.5)
102 (22.3)
85 (18.6)
80 (17.5)
74 (16.2)
75 (16.4)
62 (13.6)
70 (15.3)
49 (10.7)
87 (19.0)
210 (46.0)
2.5 (2.01, 2)

Notes: aLow FEV1% predicted defined as FEV1 ,50% predicted, high FEV1% predicted defined as FEV1 $50% predicted; bincluded family/general and internal medicine.
Abbreviations: FEV1, forced expiratory volume in 1 second; QCI, Quan–Charlson Comorbidity Index; SD, standard deviation.

Table 2 Baseline clinical characteristics from medical records

Spirometry test results
Postbronchodilator FEV1% predicted, mean (SD, median)
Postbronchodilator FEV1/FVC ratio (%), mean (SD, median)
Documented asthma diagnosis, n (%)
Yes
No
Unknown/not documented
Documented dyspnea, n (%)
Yes
No
Unknown/not documented
Documented smoking status, n (%)
Current smoker
Former smoker
Never-smoker
Unknown/not documented
Race, n (%)
Caucasian/white
African-American/black
Other
Unknown/not documented

Total
(n=754)

Low FEV1%
predicteda (n=297)

High FEV1%
predicteda (n=457)

56.6 (19.96, 56)
53.6 (11.07, 55)

37.2 (8.38, 39)
45.5 (10.71, 44)

69.1 (14.51, 66)
58.8 (7.58, 60)

142 (18.8)
232 (30.8)
380 (50.4)

51 (17.2)
84 (28.3)
162 (54.5)

91 (19.9)
148 (32.4)
218 (47.7)

552 (73.2)
82 (10.9)
120 (15.9)

230 (77.4)
21 (7.1)
46 (15.5)

322 (70.5)
61 (13.3)
74 (6.2)

163 (21.6)
408 (54.1)
35 (4.6)
148 (19.6)

58 (19.5)
162 (54.5)
12 (4.0)
65 (21.9)

105 (23.0)
246 (53.8)
23 (5.0)
83 (18.2)

609 (80.8)
18 (2.4)
5 (0.7)
122 (16.2)

246 (82.8)
5 (1.7)
1 (0.3)
45 (15.2)

363 (79.4)
13 (2.8)
4 (0.9)
77 (16.8)

Note: aLow FEV1% predicted defined as FEV1 ,50% predicted, high FEV1% predicted defined as FEV1 $50% predicted.
Abbreviations: FEV1, forced expiratory volume in 1 second; SD, standard deviation; FVC, forced vital capacity.
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any short-acting muscarinic antagonist/short-acting inhaled
β2-adrenergic agonist (73.4% vs 56.2% and 74.4% vs 54.5%),
and other COPD medications (including phosphodiesterase-4
inhibitors and xanthenes [8.1% vs 3.9% and 10.1% vs 4.4%]),
respectively (data not shown in tables or figures).

COPD exacerbations from claims data
Within the low and high groups, 52.5% vs 39.6% of patients
had any type of COPD exacerbation, including inpatient
(34.7% vs 26%), ED (13.1% vs 9.8%), and ambulatory
(23.9% vs 12.5%) exacerbations, during the 12-month
preindex (baseline) period, while 49.8% vs 36.8% had any
type of COPD exacerbation, including inpatient (20.9%
vs 16.8%), ED (10.4% vs 9.4%), and ambulatory (28.3%
vs 16.8%) exacerbations, during the 12-month postindex
period (Figure 2).

Health care resource utilization and
costs from claims data
During the 12-month preindex period, the mean total allcause health care costs for the low FEV1% predicted group
were $22,174 (SD $28,953) compared with $19,264 (SD
$24,870) for the high FEV1% predicted group (Table 3).
The mean COPD-related health care costs in the preindex
period were $10,623 (SD $14,027) for the low FEV1% predicted group compared with $7,425 (SD $13,064) for the
high FEV1% predicted group. As expected, mean costs for
each site of care (eg, hospitalization, ED visits, physician
office visit, etc) were higher for patients who had at least

$Q\&23'H[DFHUEDWLRQ
('&23'H[DFHUEDWLRQ
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3UHLQGH[


















3UHLQGH[
















3UHLQGH[

one instance of a corresponding service when compared to
the overall patient population, but the directions and patterns of the mean cost differences by low and high FEV1%
predicted were similar for the study population as a whole
(data not shown).
Overall, patients in the low FEV1% predicted group had
similar all-cause HCRU as those in the high FEV1% predicted
group during the baseline period. For COPD-related utilization, patients in the low FEV1% predicted group had a higher
mean number of physician office visits (4.3 low group vs
3.1 high group), other outpatient services (7.9 low group
vs 3.3 high group), and pharmacy claims (11.2 low group
vs 6.1 high group) compared with those in the high FEV1%
group (Table 3). Similarly to what was observed for costs,
mean utilization for each site of care (eg, hospitalization,
ED visit, physician office visit, etc) was higher for patients
who had one or more instance of corresponding service
when compared to that for the study population as a whole
(data not shown).
During the 12-month postindex period, mean total allcause costs were 24% higher for patients in the low FEV1%
predicted group than those in the high FEV1% predicted group
($27,380 [SD $38,199] low group vs $22,075 [SD $28,108]
high group; Table 4). A greater between-group difference
was observed for mean COPD-related costs, which were
56% higher in the low FEV1% predicted group compared
with the high FEV1% predicted group ($15,873 [SD $29,609]
low group vs $10,174 [SD $18,521] high group; Table 4).
All-cause and COPD-related costs were primarily driven
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3RVWLQGH[

+LJK)(9SUHGLFWHG

Figure 2 COPD exacerbations during the 12-month pre- and postindex periods.
Notes: Low FEV1% predicted defined as FEV1 ,50% predicted; high FEV1% predicted defined as FEV1 $50% predicted. The hierarchy applied to create type of COPD
exacerbation for an exacerbation episode was: inpatient COPD exacerbation . emergency department (ED) COPD exacerbation . ambulatory COPD exacerbation.
A patient could have multiple types of COPD exacerbations within the baseline (12-month preindex period) and 12-month postindex periods.
Abbreviation: FEV1, forced expiratory volume in 1 second.
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Table 3 Baseline all-cause and COPD-related health care resource utilization and costs
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Total
(n=754)
All-cause health care utilization and costsb,c
Inpatient hospitalizations
n (%)
271 (35.9)
Hospitalizations for all patients, mean (SD, median)
0.6 (1.22, 0)
Cost for all patients, mean (SD, median)
$7,252 ($17,611, $0)
ED visits
n (%)
181 (24.0)
ED visits for all patients, mean (SD, median)
0.4 (0.83, 0)
Cost for all patients, mean (SD, median)
$425 ($1,326, $0)
Physician office visits
n (%)
752 (99.7)
Physician office visits for all patients, mean
12.8 (8.39, 11)
(SD, median)
Cost of physician office visits for all patients, mean
$1,556 ($1,227, $1,252)
(SD, median)
Other outpatient services
n (%)
741 (98.3)
Other outpatient services for all patients, mean
20.6 (20.37, 14)
(SD, median)
Cost of other outpatient services for all patients,
$5,556 ($13,362, $2,564)
mean (SD, median)
Pharmacy dispensing
n (%)
743 (98.5)
Claims for all patients, mean (SD, median)
44.9 (32.53, 38)
Cost for all patients, mean (SD, median)
$5,621 ($11,356, $3,346)
Total medical costs, mean (SD, median)
$14,789 ($23,644, $6,895)
Total costs (sum of medical and pharmacy cost),
$20,411 ($26,573, $12,243)
mean (SD, median)
COPD-related health care utilization and costsb,c
Inpatient hospitalizations
n (%)
220 (29.2)
Hospitalizations for all patients, mean (SD, median)
0.5 (0.92, 0)
Cost for all patients, mean (SD, median)
$5,070 ($12,354, $0)
ED visits
n (%)
93 (12.3)
ED visits for all patients, mean (SD, median)
0.2 (0.51, 0)
Cost for all patients, mean (SD, median)
$210 ($848, $0)
Physician office visits
n (%)
674 (89.4)
Physician office visits for all patients, mean
3.6 (3.24, 3)
(SD, median)
Cost of physician office visits for all patients, mean
$425 ($449, $321)
(SD, median)
Other outpatient services
n (%)
430 (57.0)
Other outpatient services for all patients, mean
5.1 (9.56, 1)
(SD, median)
Cost of other outpatient services for all patients,
$1,027 ($3,656, $55)
mean (SD, median)
Pharmacy dispensing
n (%)
613 (81.3)
Claims for all patients, mean (SD, median)
8.1 (9.26, 5)
Cost for all patients, mean (SD, median)
$1,952 ($2,247, $1,211)
Total medical costs, mean (SD, median)
$6,732 ($13,263, $1,180)
Total costs (sum of medical and pharmacy costs),
$8,684 ($13,533, $4,214)
mean (SD, median)

Low FEV1% predicteda
(n=297)

High FEV1% predicteda
(n=457)

113 (38.0)
0.7 (1.16, 0)
$7,374 ($19,228, $0)

158 (34.6)
0.6 (1.26, 0)
$7,173 ($16,498, $0)

65 (21.9)
0.3 (0.72, 0)
$383 ($1,301, $0)

116 (25.4)
0.4 (0.89, 0)
$453 ($1,342, $0)

297 (100.0)
12.4 (8.09, 10)

455 (99.6)
13.1 (8.58, 12)

$1,491 ($1,154, $1,227)

$1,598 ($1,272, $1,258)

291 (98.0)
22.3 (22.20, 17)

450 (98.5)
19.4 (19.02, 14)

$5,553 ($12,346, $2,661)

$5,558 ($13,996, $2,487)

290 (97.6)
48.0 (32.83, 41)
$7,374 ($15,647, $4,246)
$14,801 ($23,928, $7,284)
$22,174 ($28,953, $13,262)

453 (99.1)
42.9 (32.22, 37)
$4,483 ($7,124, $2,919)
$14,782 ($23,484, $6,652)
$19,264 ($24,870, $11,149)

101 (34.0)
0.5 (0.93, 0)
$5,617 ($12,154, $0)

119 (26.0)
0.4 (0.91, 0)
$4,714 ($12,483, $0)

42 (14.1)
0.2 (0.49, 0)
$260 ($1,081, $0)

51 (11.2)
0.2 (0.53, 0)
$178 ($654, $0)

272 (91.6)
4.3 (3.56, 4)

402 (88.0)
3.1 (2.90, 2)

$510 ($501, $380)

$370 ($403, $277)

196 (66.0)
7.9 (11.66, 2)

234 (51.2)
3.3 (7.37, 1)

$1,536 ($5,255, $242)

$697 ($1,967, $10)

261 (87.9)
11.2 (10.70, 9)
$2,700 ($2,636, $2,039)
$7,922 ($13,647, $2,300)
$10,623 ($14,027, $6,142)

352 (77.0)
6.1 (7.53, 4)
$1,466 ($1,795, $729)
$5,959 ($12,964, $701)
$7,425 ($13,064, $3,072)

Notes: aLow FEV1 predicted was defined as FEV1 50% predicted; high FEV1 predicted was defined as FEV1 50% predicted. bBaseline all-cause and COPD-related healthcare
resource utilization and costs were measured in the 12-month preindex period. cCosts were adjusted to 2014 US dollars given the most accurate and updated medical care
price index information provided by the Bureau of Labor Statistics.
Abbreviations: ED, emergency department; FEV1, forced expiratory volume in 1 second; SD, standard deviation.
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Table 4 12-month postindex all-cause and COPD-related health care resource utilization and costs

All-cause health care utilization and costsb,c
Inpatient hospitalizations
n (%)
Hospitalizations for all patients, mean (SD, median)
Cost for all patients, mean (SD, median)
ED visits
n (%)
ED visits for all patients, mean (SD, median)
Cost for all patients, mean (SD, median)
Physician office visits
Physician office visits, n (%)
Physician office visits for all patients, mean
(SD, median)
Cost of physician office visits for all patients, mean
(SD, median)
Other outpatient services
n (%)
Other outpatient services for all patients, mean
(SD, median)
Cost of other outpatient services for all patients, mean
(SD, median)
Pharmacy dispensing
Pharmacy dispensing, n (%)
Claims for all patients, mean (SD, median)
Cost for all patients, mean (SD, median)
Total medical costs, mean (SD, median)
Total costs (sum of medical and pharmacy costs), mean
(SD, median)
COPD-related health care utilization and costsb,c
Inpatient hospitalizations
n (%)
Hospitalizations for all patients, mean (SD, median)
Cost for all patients, mean (SD, median)
ED visits
n (%)
ED visits for all patients, mean (SD, median)
Cost for all patients, mean (SD, median)
Physician office visits
n (%)
Physician office visits for all patients, mean
(SD, median)
Cost of physician office visits for all patients, mean
(SD, median)
Other outpatient services
n (%)
Other outpatient services for all patients, mean
(SD, median)
Cost of other outpatient services for all patients, mean
(SD, median)
Pharmacy dispensing
n (%)
Claims for all patients, mean (SD, median)
Cost for all patients, mean (SD, median)
Total COPD-related medical costs, mean (SD, median)
Total COPD-related costs (sum of medical and
pharmacy costs), mean (SD, median)

Total
(n=754)

Low FEV1% predicteda
(n=297)

High FEV1% predicteda
(n=457)

250 (33.4)
0.6 (1.24, 0)
$8.846 ($22,858, $0)

107 (36.0)
0.7 (1.28, 0)
$10,224 ($27,293, $0)

145 (31.7)
0.6 (1.22, 0)
$7,951 ($19,422, $0)

202 (26.8)
0.4 (1.28, 0)
$552 ($1,829, $0)

83 (27.9)
0.4 (0.78, 0)
$476 ($1,450, $0)

119 (26.0)
0.5 (1.53, 0)
$601 ($2,038, $0)

753 (99.9)
13.5 (9.00, 12)

297 (100.0)
13.2 (8.37, 12)

456 (99.8)
13.7 (9.39, 12)

$1,755 ($1,804, $1,370)

$1,649 ($1,341, 1,328)

$1,823 ($2,048, $1,406)

747 (99.1)
23.6 (22.30, 19)

296 (99.7)
27.3 (25.96, 23)

451 (98.7)
21.3 (19.22, 16)

$6,322 ($13,654, $3,057)

$6,516 ($13,978, $3,114)

$6,196 ($13,454, $2,929)

747 (99.1)
49.4 (33.77, 43)
$6,690 ($13,766, $3,829)
$17,475 ($29,490, $6,888)
$24,165 ($32,539, $12,826)

295 (99.3)
52.2 (33.67, 46)
$8,515 ($18,734, $4,810)
$18,865 ($34,217, $7,525)
$27,380 ($38,199, $14,747)

452 (98.9)
47.5 (33.74, 42)
$5,504 ($9,031, $3,375)
$16,571 ($25,961, $6,552)
$22,075 ($28,108, $11,915)

216 (28.6)
0.5 (1.01, 0)
$7,625 ($21,785, $0)

101 (34.0)
0.6 (1.11, 0)
$9,367 ($26,658, $0)

115 (25.2)
0.4 (0.94, 0)
$6,493 ($17,864, $0)

113 (15.0)
0.2 (0.80, 0)
$257 ($1,039, $0)

49 (16.5)
0.2 (0.53, 0)
$247 ($9,807, $0)

64 (14.0)
0.2 (0.94, 0)
$263 ($1,166, $0)

713 (94.6)
4.5 (3.64, 42)

292 (98.3)
5.4 (3.91, 4)

421 (92.1)
3.9 (3.32, 3)

$571 ($606, $435)

$695 ($737, $530)

$491 ($488, $387)

547 (72.5)
7.2 (11.13, 2)

235 (79.1)
11.2 (13.97, 5)

312 (68.3)
4.6 (7.81, 1)

$1,624 ($6,420, $291)

$2,517 ($9,500, $916)

$1,044 ($2,937, $225)

630 (83.6)
9.2 (9.64, 7)
$2,341 ($2,475, $1,616)
$10,077 ($23,575, $1,769)
$12,419 ($23,667, $4,901)

270 (90.9)
12.2 (11.27, 9)
$3,047 ($2,902, $2,549)
$12,826 ($29,503, $2,620)
$15,873 ($29,609, $6,868)

360 (78.8)
7.3 (7.84, 5)
$1,883 ($2,029, $1,371)
$8,291 ($18,565, $1,034)
$10,174 ($18,521, $3,918)

Notes: aLow FEV1% predicted defined as FEV1 ,50% predicted, high FEV1% predicted defined as FEV1 $50% predicted; bevents on index date included in 12-month postindex
period; ccosts adjusted to 2014 US dollars, given the most accurate and updated medical care price index information provided by the Bureau of Labor Statistics.
Abbreviations: ED, emergency department; FEV1, forced expiratory volume in 1 second; SD, standard deviation.
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by expenditures for inpatient hospitalizations, followed by
medications and other outpatient services.
Follow-up all-cause health care utilization of hospitalization, ED visits, and physician office visits were similar
between the low and high FEV1% predicted groups. Patients
in the low FEV1% predicted group had a higher mean number
of other outpatient services (27.3 [SD 25.96]) compared to
the high FEV1% predicted group (21.3 [SD 19.22]). They
also had higher mean prescription costs compared with the
high FEV1% predicted group ($8,515 [SD $18,734] vs $5,504
[SD $9,031], respectively) (Table 4).
During the follow-up period, the low FEV1% predicted
group had a higher percentage of COPD-related inpatient
hospitalizations (34.0% vs 25.2%) and higher mean inpatient
costs ($9,367 [SD $26,658]) vs ($6,493 [SD $17,864]) compared to the high group. The low FEV1% predicted group also
had a higher mean number of physician office visits (5.4 [SD

3.91] vs 3.9 [SD 3.32]) and associated costs ($695 [SD $737]
vs $491 [SD $488]), as well as a higher mean number of
other outpatient visits (11.2 [SD 13.97] vs 4.6 [SD 7.81])
and mean costs ($2,517 [SD $9,500] vs $1,044 [SD $2,937])
compared to the high group. Pharmacy prescription utilization was higher among patients in the low FEV1% predicted
group (90.9% vs 78.8%), and associated mean costs were
also higher for the low FEV1% predicted group ($3,047
[SD $2,902] vs $1,883 [SD $2,029]) (Table 4).

Multivariable analysis
Multivariable logistic regression results indicated that any
LABA use (single or combination therapy; odds ratio [OR]
1.95, 95% confidence interval [CI] 1.04–3.65; P=0.0372)
and low FEV1% predicted (OR 1.39, 95% CI 1.01–1.92;
P=0.0459) were predictors of COPD exacerbations
(Figure 3), while LAMA use (single or combination therapy)
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Figure 3 Factors associated with COPD exacerbations within the 12-month postindex period.
Notes: Low FEV1% predicted defined as FEV1 ,50% predicted; high FEV1% predicted defined as FEV1 $50% predicted. Logistic regression was performed with the dependent
variable as the occurrence of COPD exacerbations within the 12-month postindex period. Odds ratios and 95% confidence intervals are reported in this figure.
Abbreviations: FEV1, forced expiratory volume in 1 second; PCP, primary care physician; ICS, inhaled corticosteroids; LABA, long-acting β-agonist; LAMA, long-acting
muscarinic agent; SAMA, short-acting muscarinic antagonist; SABA, short-acting (inhaled) β2-adrenergic agonist; PDE4 inhibitors, phosphodiesterase-4 inhibitors.
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Figure 4 Factors associated with COPD-related health care costs within the 12-month postindex period.
Notes: Low FEV1% predicted defined as FEV1 ,50% predicted; high FEV1% predicted defined as FEV1 $50% predicted. Generalized linear models with gamma distribution
and log link were performed with the dependent variable as COPD-related medical and pharmacy costs within the 12-month postindex period. Exponentiated coefficients
and their corresponding 95% confidence intervals are reported in this figure.
Abbreviations: FEV1, forced expiratory volume in 1 second; PCP, primary care physician; ICS, inhaled corticosteroids; LABA, long-acting β-agonist; LAMA, long-acting
muscarinic agent; SAMA, short-acting muscarinic antagonist; SABA, short-acting (inhaled) β2-adrenergic agonists; PDE4 inhibitors, phosphodiesterase-4 inhibitors.

was identified as a protective factor against COPD exacerbations (OR 0.72, 95% CI 0.52–1.00; P=0.0472).
Results from the cost analyses using generalized linear
models with gamma distribution and log link showed that
age 65–74 years (coefficient 0.31, standard error [SE]
0.11; P=0.0066) or 75 years or older (coefficient 0.43,
SE 0.12; P=0.0003), higher Quan–Charlson Comorbidity Index score (coefficient 0.05, SE 0.02; P=0.0248),
asthma (coefficient 0.23, SE 0.11; P=0.0480), oxygen
therapy (coefficient 0.66, SE 0.11; P,0.0001), any ICS
(coefficient 0.39, SE 0.18; P=0.0291), and low FEV1%
predicted (coefficient 0.28, SE 0.10; P=0.0064) were
positively associated with COPD-related costs. Pulmonologist as provider specialty (coefficient -0.34, SE
0.11; P=0.0018) was significantly associated with lower
COPD-related costs compared to primary care physicians
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(Figure 4). However, low/high FEV1% predicted was not
a significant predictor for all-cause health care costs (data
not shown).

Discussion
This observational study presents real-world information
on the demographic, clinical, and economic profiles of
patients with COPD. Our results suggest that patients with
low baseline FEV1% predicted levels tend to have greater
utilization of COPD medications, more COPD exacerbations,
and higher COPD-related health care costs compared with
patients having high baseline FEV 1% predicted levels.
Additionally, multivariable modeling showed that having
a low baseline FEV1% predicted level was a significant
predictor of COPD exacerbations and higher COPD-related
health care costs.
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A significant proportion (15%–20%) of COPD patients
also have a clinical diagnosis of asthma.33–36 Patients who met
all study inclusion criteria and had a diagnosis of asthma were
included in the study to reflect real-world practice.
The prevalence of any COPD exacerbations was higher in
the low FEV1% predicted group than in the high FEV1% predicted group for both the 12-month preindex and 12-month
postindex periods. Patients in the low FEV1% predicted group
had greater COPD-related costs than those in the high FEV1%
predicted group during both the baseline and follow-up
periods. Within the 12-month postindex period, patients in
the low FEV1% predicted group had greater COPD-related
utilization, including inpatient hospitalizations, physician
office visits, other outpatient services, and pharmacy claims
and associated costs. These findings are consistent with
previous research, which demonstrated improvements in
FEV1% predicted were significantly related to a decrease in
COPD symptoms, as well as reduced COPD exacerbations
and rescue-medication use.7,8,11,13–15 In contrast to findings
from previous studies using only administrative claims
data,37–41 our results, which included both a claims-based
COPD exacerbation indicator and an FEV1 status indicator
from medical records, showed that in analyses that included
both variables, prior claims-based exacerbations were no
longer significantly associated with postindex exacerbations
when FEV1 status was included in multivariable analyses.
Multivariable modeling identified LAMAs (single or
combination therapy) as predictive of fewer COPD exacerbations, which is consistent with clinical studies supporting
the efficacy of LAMAs in reducing COPD exacerbations.42–45
Conversely, the multivariable analyses identified LABAs
(single or combination therapy) as predictive of COPD
exacerbations, a result likely due to indication bias that
ICS–LABA combinations are likely to be prescribed to
more severe COPD patients or those with a history of
exacerbations,43,46 and the vast majority (96.6%) of patients
on baseline LABA therapies were taking ICS–LABA combination therapies in this study. Additionally, several studies
identified LAMAs to be the superior therapy over LABAs,
when compared, in decreasing the risk for moderate-to-severe
COPD exacerbations.42–45
By using both administrative claims and medical records
from a large US managed-care population, this study
describes the impact of lung function on HCRU and costs in a
real-world population. While it has been well established that
poor lung function is correlated with increased symptoms and
exacerbations,7–17 and that exacerbations are associated with
increased costs,16,17 the study results expand upon previous
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findings of the relationship between clinically determined
lung function measured by spirometry, HCRU, and costs
using more recent data compared to previous studies.18–30
The study results confirm that lung function (FEV1) may be
a useful way for providers to identify and monitor respiratory impairment in COPD patients. Payers should recognize
the importance of lung function as it relates to health care
utilization and costs. Therefore, health plans may want to
encourage providers to conduct periodic spirometry testing
for optimal management of COPD patients.
The study results need to be interpreted in light of several
study limitations. As with all claims-based analyses, the study
results may not be generalizable to patients with other types
of health insurance or those living outside the US, because all
study participants were members of a large US commercial
health plan. Data were obtained from administrative claims,
which are primarily intended for reimbursement rather than
research purposes. The claims may have contained undetected coding errors, incomplete claims, unreliable clinical
coding, or other unobservable factors that may have influenced the study outcomes.
There are also limitations associated with the use of medical record data. A high proportion of patients were excluded
from the analyses because they had no spirometry results
documented in their medical records during the observation
period, despite having a medical claim indicating a spirometry test. Because spirometry is the most objective means of
measuring COPD severity and is required for confirmation
of a COPD diagnosis,10 and patients had at least one medical
claim for a spirometry test during the medical record review
period, the lack of spirometry results may be a reflection of
incomplete record-keeping or documentation issues rather
than an indication that spirometry tests were not performed.
Also, other issues involving use of medical records include
missing medical records, the inability to locate needed
information in the medical record, and vague, incomplete,
or illegible medical records. In addition, data collected from
medical record abstractions may contain measurement errors
due to inconsistent coding of data into categories and mistakes in transcription of information from medical records
to a computer database. Furthermore, facilities that provided
medical records may be different from those that did not
respond to requests or refused to participate.
Finally, several limitations were related to the study
design. Data were collected at one point in time (ie, changes
in postbronchodilator FEV1% predicted over time were not
captured). In addition, FEV1 measurements may not be comparable, since they are highly variable and may be influenced
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by a number of technical and measurement factors and
seasonal and diurnal variation, which may not be controlled
for using the observational study design. Lastly, the patient
cohort was stratified into two groups (high [mild or moderate] vs low [severe or very severe]) instead of four groups
according to the classification of severity of airflow limitation
in COPD specified in the 2014 GOLD report.2 However, in
this study sample, we did not expect significant clinical and
cost differences between the mild and moderate groups or
severe and very severe groups based on our exploration of
the data.

Conclusion
Real-world data demonstrate that patients with COPD who
have low FEV1% predicted levels use more COPD medications, have more COPD exacerbations, and incur higher
COPD-related health care costs than patients with COPD
who have high FEV1% predicted levels. Health plans should
encourage spirometry testing by providers as a means of
monitoring respiratory impairment of patients with COPD
to improve the management of their care.
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Figure S1 Claim-based sample identification process.
Note: *Index date, date of first medical claim for spirometry during intake period from July 1, 2012 to June 30, 2013.
Abbreviation: ED, emergency department.
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Figure S2 Medical record sample identification process.
Note: *Medical records received after medical record abstraction cutoff date.
Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
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